<DOC>
	<DOCNO>NCT00278239</DOCNO>
	<brief_summary>RATIONALE : Questionnaires measure quality life may improve ability plan treatment patient primitive neuroectodermal tumor . PURPOSE : This phase III trial study quality life patient undergo previous treatment primitive neuroectodermal tumor .</brief_summary>
	<brief_title>Quality Life Patients Who Have Undergone Previous Treatment Primitive Neuroectodermal Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine quality survival patient UK European country enrol previous International Society Pediatric Oncology ( SIOP ) 2 3 phase III trial treatment pediatric primitive neuroectodermal tumor ( PNET ) . - Compare quality survival child allocate different treatment trial . Secondary - Determine framework allow similar information collect across participate country PNET 4 trial open autumn 2002 . OUTLINE : This cross-sectional , multicenter study . Pediatric oncologist , teacher , patient â‰¥ 12 year old , parent child age 3-11 year old complete six questionnaire assess patient ' motor sensory function , cognition , behavior , emotion , educational provision achievement , social integration , subjective experience patient family . PROJECTED ACCRUAL : A total 229 patient accrue study .</detailed_description>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Surviving primitive neuroectodermal tumor ( PNET ) patient previously enrol International Pediatric Oncology Society ( SIOP ) 2 3 phase III treatment trial Surviving PNET patient eligible treated accord PNET 3 protocol randomize No metastatic disease time allocation treatment No current progressive disease PATIENT CHARACTERISTICS : No patient deem unsuitable study treat clinician PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>24 Years</maximum_age>
	<verification_date>April 2006</verification_date>
	<keyword>long-term effect secondary cancer therapy child</keyword>
	<keyword>psychosocial effect cancer treatment</keyword>
	<keyword>cognitive/functional effect</keyword>
	<keyword>childhood supratentorial primitive neuroectodermal tumor</keyword>
</DOC>